Trials / Recruiting
RecruitingNCT06240143
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | intradermal |
| DRUG | Nivolumab | intradermal |
| DRUG | Nivolumab | intravenous |
Timeline
- Start date
- 2024-03-08
- Primary completion
- 2029-07-01
- Completion
- 2034-03-01
- First posted
- 2024-02-02
- Last updated
- 2024-11-14
Locations
6 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT06240143. Inclusion in this directory is not an endorsement.